US · CTKB
Cytek Biosciences, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Fremont, CA 94538
- Website
- cytekbio.com
Price · as of 2025-12-31
$4.62
Market cap 572.83M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $31.22 | +575.76% |
| Intrinsic Value(DCF) | $2.42 | -47.62% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.61 | $9.62 | |||
| 2021 | $12.42 | $38.60 | $49.25 | $3.06 | $0.99 |
| 2022 | $9.11 | $58.39 | $48.92 | $3.18 | $0.67 |
| 2023 | $7.12 | $37.17 | $7.69 | $2.34 | $0.00 |
| 2024 | $4.53 | $25.04 | $1.19 | $2.67 | $0.00 |
| 2025 | $4.43 | $31.22 | $1.10 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Cytek Biosciences, Inc.'s (CTKB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $31.22
- Current price
- $4.62
- AI upside
- +575.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2.42
-47.62% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CTKB | Cytek Biosciences, Inc. | $4.62 | 572.83M | +576% | -48% | — | — | -8.51 | 1.66 | 2.81 | -18.31 | -0.83 | 1.84 | 51.84% | -20.04% | -33.02% | -18.05% | -35.25% | -13.85% | 0.04 | -85.20 | 5.04 | 4.16 | 4.42 | 102798.00% | 52.00% | -14013.00% | -1.55% | -0.06 | -7.65% | 0.00% | 0.00% | 0.00% | -7.88 | -36.31 | 1.58 | 3.49 |
| ANGO | AngioDynamics, Inc. | $11.44 | 471.53M | +233% | -70% | -97% | — | -10.26 | 1.91 | 1.19 | 168.52 | — | 3.06 | 53.92% | -13.66% | -11.62% | -17.50% | -30.54% | -11.37% | 0.00 | — | 2.21 | 1.30 | -32.16 | -8192.00% | -376.00% | -5699.00% | -4.18% | -0.13 | -11.17% | 0.00% | 0.00% | 0.48% | -7.33 | -20.07 | 1.00 | 0.98 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| CLPT | ClearPoint Neuro, Inc. | $12.57 | 373.94M | +192% | -56% | — | — | -18.68 | 13.91 | 11.25 | -18.87 | — | 14.18 | 60.92% | -62.91% | -60.25% | -81.24% | -189.62% | -46.22% | 0.14 | — | 3.22 | 2.40 | 0.93 | -2222.00% | 3104.00% | -3610.00% | -2.61% | -0.86 | -88.59% | 0.00% | 0.00% | 2.08% | -17.05 | -36.50 | 10.73 | 8.37 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| ORGO | Organogenesis Holdings In… | $3.21 | 407.39M | +1,529% | +5,869% | -5% | +241% | 10.27 | 1.27 | 0.67 | 5.43 | — | 1.45 | 73.57% | 7.92% | 10.09% | 10.81% | 15.37% | 6.75% | 0.27 | 19.59 | 3.62 | 3.11 | -0.17 | -160000.00% | 1704.00% | -68573.00% | -6.43% | -0.10 | -8.41% | 2.99% | 30.70% | 2.99% | 8.25 | -15.07 | 0.65 | 3.09 |
| SRDX | Surmodics, Inc. | $42.98 | 614.51M | +203% | -62% | -97% | — | -49.05 | 4.76 | 4.49 | 118.28 | -7.60 | 11.17 | 73.81% | -4.48% | -9.15% | -9.67% | -5.14% | -6.34% | 0.28 | -1.59 | 3.96 | 3.09 | -0.61 | 64545.00% | -491.00% | -14271.00% | -0.57% | 0.01 | -2.95% | 0.00% | 0.00% | 0.00% | -99.07 | -172.40 | 4.44 | 7.30 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
- CEO
- Wenbin Jiang
- Employees
- 663
- Beta
- 1.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2.42 ÷ $4.62) − 1 = -47.62% (DCF, example).